Loading
When slow CLL suddenly turns into an aggressive lymphoma. Rare, hard to treat, and the focus of new immunotherapy trials.
Occurs in 2-10% of CLL, usually as clonally related diffuse large B-cell lymphoma; median survival historically under a year. Chemoimmunotherapy is poor; PD-1 blockade with BTK inhibition (zanubrutinib-tislelizumab RT1 trial, ORR ~58%), pirtobrutinib, venetoclax-based combinations, CD20×CD3 bispecifics (epcoritamab, glofitamab), and CAR-T show activity. Allogeneic transplant for responders.
Showing the molecule this term concerns: Pirtobrutinib.
Shares Pirtobrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Pirtobrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Richter transformation of chronic lymphocytic leukaemia, Relapsed or refractory chronic lymphocytic leukaemia, T-cell engagers (bispecific), Chronic lymphocytic leukaemia.
Shares Pirtobrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Pirtobrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Pirtobrutinib, Glofitamab.
Shares Pirtobrutinib, Zanubrutinib.
Shares Pirtobrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.